

PUBLIC SUMMARY DOCUMENT

Product: Dansac NovaLife
Applicant: Dansac
Date of SPAP Meeting: 12 October 2021

1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Dansac, sought the deletion of two variants of Dansac NovaLife (SAS Code 5671L) in subgroup 4(a) of the Stoma Appliance Scheme (the Scheme) Schedule, due to the two variants being discontinued. The products, including 11 variants, are currently listed at a unit price of \$4.142, with a maximum monthly quantity of 30 units.

2. Substitute products

The nominated substitute products are variants of Dansac NovaLife TRE Flat Baseplate (SAS Code 80201D) in the same subgroup. The products, including eight variants, are currently listed at a unit price of \$4.142, with a maximum monthly quantity of 30 units.

Variants to be deleted

Product Code	Description
1736-20	belt loops on pouch, 36mm ring, 1.1mm, hydrocolloid baseplate, flat, self-adhesive, standard wear, oval, pre-cut, 20mm, 28mm,
1770-45	belt loops on pouch, 70mm ring, 1.1mm, hydrocolloid baseplate, flat, self-adhesive, standard wear, oval, pre-cut, 45mm, 62mm,

Nominated substitute – SAS Code 80201D

Product Code	Description
3136-15	belt loops on each side of the pouch, mechanical coupling, 36mm ring, floating flange, 0.7mm, hydrocolloid baseplate, hydrocolloid self-adhesive, standard wear, oval, cut-to-fit, 15mm, release tabs, 28mm,
3170-15	belt loops on each side of the pouch, mechanical coupling, 70mm ring, floating flange, 0.7mm, hydrocolloid baseplate, hydrocolloid self-adhesive, standard wear, oval, cut-to-fit, 15mm, release tabs, 62mm,

3. Background

This product was first listed on the Scheme Schedule on 21 November 2011.

4. Clinical Place for the Product

The proposed substitute products provide an alternative for users requiring a two-piece baseplate pouch with flat mechanical coupling.

Financial Analysis

The substitute product is currently listed in subgroup 4(a) of the Scheme Schedule at the same cost and maximum monthly quantity. It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of deleting these two variants.

5. Panel Recommendation

The Panel recommended the deletion of two variants of Dansac NovaLife (SAS Code 5671L) in subgroup 4(a) of the Scheme Schedule at the unit price of \$4.142, with a maximum monthly quantity of 30 units.

The Panel also noted that Dansac is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletions. A period of approximately six months from the date of the Panel's recommendation (12 October 2021) should be given to allow users of the products to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

6. Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context.

A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

7. Applicant's Comment

Dansac agrees with the SPAP recommendation.